Unsettling Developments for Plavix

Bristol-Myers Squibb Co. and Sanofi-Aventis are anxiously awaiting the outcome of an antitrust review of a proposed patent settlement with Apotex Inc. over the timing of a generic launch of clopidogrel (Plavix). They have reason to sweat: it sounds like the Federal Trade Commission is spoiling for a fight.